Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > COVID surging

<< Previous

Bullboard Posts

Next >>

Comment by AngelaLon Jul 30, 2021 10:43am

226 Views

Post# 33631865

RE:RE:RE:RE:RE:RE:COVID surging

The peak immediately post split was 75 cents. I had predicted 90 cents. That has sold down as shorters have come in. I predict that short covering will now come into play and the share price will rise in the near term, perhaps to $1.60. It won't take much much panic short-covering to get there.

<< Previous

Bullboard Posts

Next >>

Anaergia expands relationship with PepsiCo